Roquebert Bénédicte, Wirden Marc, Simon Anne, Deval Jérome, Katlama Christine, Calvez Vincent, Marcelin Anne-Geneviève
Department of Virology, Pitié-Salpêtrière Hospital and UPRES EA 2387, Université Pierre et Marie Curie, Paris, France.
J Med Virol. 2007 Mar;79(3):207-11. doi: 10.1002/jmv.20788.
Recent studies have highlighted the need of investigating the in vivo role of ribonuclease H (RNase H) in nucleoside reverse transcriptase inhibitors (NRTIs) resistance. The prevalence of RNase H mutations in naive and in NRTI pre-treated patients in regimen failure were compared and some specific associations between NRTI resistance mutations and RNase H mutations were determined. Four positions were mutated more frequently in pre-treated patients than in naive patients: L469T/I/M/H, T470P/S/E/K, A554T/L/K, and K558R/G/E. Mutations at position K558 were also associated with the number of thymidine analog mutations (TAMs). These results suggest that these mutations could play a role in NRTI resistance.
最近的研究强调了研究核糖核酸酶H(RNase H)在核苷类逆转录酶抑制剂(NRTIs)耐药性中的体内作用的必要性。比较了初治患者和接受NRTIs预处理且治疗方案失败的患者中RNase H突变的发生率,并确定了NRTIs耐药性突变与RNase H突变之间的一些特定关联。在接受预处理的患者中,有四个位点的突变比初治患者更频繁:L469T/I/M/H、T470P/S/E/K、A554T/L/K和K558R/G/E。K558位点的突变也与胸苷类似物突变(TAMs)的数量有关。这些结果表明,这些突变可能在NRTIs耐药性中起作用。